This is the scenario dose escalation risks creating and exactly why staying within evidence-supported doses, combined with the recovery windows built into the 3-on-4-off schedule, matters so much
[DOI] [PMC free article] [PubMed] [Google Scholar] 114.Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.I., De Marzo A.M., Van Eyk J.E., Mendell J.T., et al
Although this remains to be confirmed, this candidate biomarker does not appear discriminative for disease stage and fertility status, but seems impacted by menstrual cycle phases [22]
Peer review Peer review information Nature Chemical Biology thanks Hai-Xin Yuan and the other, anonymous reviewer(s) for their contribution to the peer review of this work
Targeting the MAPK pathway in KRAS-driven tumors
The products offered are for in-vitro laboratory research use only